Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review
- PMID: 28582760
- DOI: 10.1016/j.biopha.2017.05.125
Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review
Erratum in
-
Corrigendum to "Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review" [Biomed. Pharmacother. 92 (2017) 681-689].Biomed Pharmacother. 2018 May;101:820. doi: 10.1016/j.biopha.2018.02.102. Epub 2018 Mar 22. Biomed Pharmacother. 2018. PMID: 29525678 No abstract available.
Abstract
Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.
Keywords: FDA approved drugs; GBM chemotherapy; Natural anti-glioma; Novel anti-glioma; Synthetic anti-glioma.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical